BioSpace News Archive

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today it will ring the Nasdaq Closing Bell on October 22 in honor of National Depression Awareness Month.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that, together with LEO Pharma A/S (“LEO Pharma”) it has entered into a settlement and license agreement with an affiliate of Teva Pharmaceuticals Industries Ltd. (“Teva”) to resolve pending patent litigation involving Finacea® Foam.

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced today that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with growth hormone deficiency (GHD) met its primary endpoint of non-inferiority to daily GENOTROPIN® (somatropin) for injection, as measured by annual height velocity at 12 months.

Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that five posters related to its investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution), will be presented at the 48th Annual Meeting of the Child Neurology Society (CNS) being held in Charlotte, North Carolina, from October 23-26, 2019.

Tetra Bio-PharmaInc. (“Tetra” or “TBP”) today provides an update on its initiatives to bring its Caumz® (PPP011) inhalation drug product to the market.

Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc., announced the U.S. launch of PreserVision® AREDS 2 Formula minigel eye vitamins.

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announces it will host a webcast to present the company’s interim keloid and hypertrophic scar proof-of-concept (“POC”) trial data on October 25, 2019 at 5:30 p.m. ET.

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will webcast its Quarterly Update Conference Call for the third quarter 2019 on Tuesday, November 12 at 4:30 p.m. ET / 1:30 p.m. PT.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences.

Tangible® Science, LLC, an innovator creating a dramatically better contact lens experience for patients and eye care practices, today announced that gas permeable (GP) contact lens materials from Acuity Polymers, Bausch + Lomb, Contamac®, Paragon and SynergEyes® are now available for coating with Tangible® Hydra-PEG®.